Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Covalon TechnologiesCVALF 83 Earnings Yield (Joel Greenblatt) % is 3.26% as of Mar. 2026. GuruFocus rates CVALF with a GF Score™ of 83/100 and a GF Value™ of $1.54 (Fairly Valued). The stock has 2 warning signs investors should review. Among 853 Medical Devices & Instruments companies, Covalon Technologies ranks better than 59.2% on this metric.
Covalon Technologies's Enterprise Value for the quarter that ended in Mar. 2026 was $25.12 Mil.
Covalon Technologies's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $0.83 Mil. Covalon Technologies's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was 3.26%.
The historical rank and industry rank for Covalon Technologies's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
CVALF'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -31.36 Med: -4.22 Max: 10.52
Current: 2.78
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Covalon Technologies was 10.52%. The lowest was -31.36%. And the median was -4.22%.
CVALF's Earnings Yield (Joel Greenblatt) % is ranked better than 59.2% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 0.76
vs CVALF: 2.78
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Covalon Technologies's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Covalon Technologies Earnings Yield (Joel Greenblatt) % Related Terms
Covalon Technologies Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Covalon Technologies's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Covalon Technologies's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Covalon Technologies Earnings Yield (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Covalon Technologies's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Covalon Technologies's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Covalon Technologiess Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Sep. 2025 is calculated as
Covalon Technologies's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.83 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 3.26% mean?
Covalon Technologies (CVALF) has a Earnings Yield (Joel Greenblatt) % of 3.26% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Covalon Technologies and its competitors. According to the industry distribution chart, Covalon Technologies ranks #348 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 40.8%.
Is Covalon Technologies' Earnings Yield (Joel Greenblatt) % too high?
Covalon Technologies' current Earnings Yield (Joel Greenblatt) % is 3.26%. The Medical Devices & Instruments industry median Earnings Yield (Joel Greenblatt) % is 0.76. Covalon Technologies' value of 3.26% is 328.9% above this industry median. Based on the distribution chart, Covalon Technologies ranks #348 out of 853 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Covalon Technologies has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Covalon Technologies' Earnings Yield (Joel Greenblatt) % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Covalon Technologies ranks #348 out of 853 companies for Earnings Yield (Joel Greenblatt) %. This puts Covalon Technologies in the upper half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 0.76. Covalon Technologies' value of 3.26% is 328.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median Earnings Yield (Joel Greenblatt) % among Medical Devices & Instruments companies is 0.76, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Covalon Technologies's current Earnings Yield (Joel Greenblatt) % of 3.26% is 328.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Covalon Technologies and its competitors. For the Medical Devices & Instruments industry, the median Earnings Yield (Joel Greenblatt) % is 0.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Covalon Technologies's current Earnings Yield (Joel Greenblatt) % is 3.26%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Covalon Technologies stock overvalued right now?
Based on GuruFocus' analysis, Covalon Technologies (CVALF) is currently considered Fairly Valued. The stock's GF Value™ is $1.54, compared to a current price of $1.48 — trading 4.2% below its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 3.26% and 328.9% above the Medical Devices & Instruments industry median of 0.76. Covalon Technologies' overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Covalon Technologies (CVALF), the current Earnings Yield (Joel Greenblatt) % is 3.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Covalon Technologies (CVALF) Overvalued in 2026?
Based on GuruFocus' analysis, Covalon Technologies stock appears to be undervalued.
The current stock price of $1.48 is trading 4.2% below its estimated GF Value™ of $1.54.
GuruFocus considers Covalon Technologies to be Fairly Valued.
Key valuation signals for CVALF:
Earnings Yield (Joel Greenblatt) %: 3.26%
GF Value™: $1.54 vs. price of $1.48 (4.2% below fair value)
Industry Position: 328.9% above the Medical Devices & Instruments median (#348 of 853)
No single metric tells the full story. See the CVALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Covalon Technologies Ltd is engaged in the business of researching, developing, manufacturing, and marketing patent-protected medical products that improve patient outcomes in the areas of infection management, wound care, and surgical procedures. The company generates revenue through development contracts, licensing agreements, distribution contracts, and sales. Its products include IV dressings, surgical site protection products, vascular access protection products, and others, and its solutions include primary dressing cover, vascular access technologies, advanced wound care, sensitive skin solutions, custom medical coatings, and patient resource support.
83GF Score
Get the complete analysis for CVALF
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVALF has been successfully added to your 
